PURPOSE: It has been suggested that FDG PET has predictive value for the prognosis of treated oesophageal carcinoma. However, the studies reported in the literature have shown discordant results. The aim of this study was to determine whether pretherapy quantitative metabolic parameters correlate with patient outcomes. METHODS: Included in the study were 67 patients with a histological diagnosis of oesophageal squamous cell carcinoma. Each patient underwent (18)F-FDG PET (4.5 MBq/kg) before chemoradiotherapy. Quantitative analysis was performed using the following parameters: age, weight loss, location, N stage, OMS performance status, MTVp and MTVp' (metabolic tumour volume determined by two different physicians), MTV40% (volume for a threshold of 40 % of SUVmax), MTVa (volume automatically determined with a contrast-based adaptive threshold method), SUVmax, SUVmean and TLG (total lesion glycolysis). RESULTS: MTVp and MTV40% were highly correlated (Pearson's index 0.92). SUVmeanp and SUVmean40% were also correlated (Pearson's index 0.86), as were TLGp and TLG40% (Pearson's index 0.98). Similarly, the parameters obtained with the adaptive threshold method (MTVa, SUVmeana and TLGa) were correlated with those obtained manually (MTVp, SUVmeanp and TLGp). The manual metabolic tumour volume determination (MTVp and MTVp') was reproducible. Multivariate analysis for disease-free survival (DFS) showed that a larger MTVp was associated with a shorter DFS (p = 0.004) and that a higher SUVmax was associated with a longer DFS (p = 0.02). Multivariate analysis for overall survival (OS) showed that a larger MTVp was associated with a shorter OS (p = 0.01) and that a tumour in the distal oesophagus was associated with a longer OS (p = 0.005). The associations among the other parameters were not statistically significant. CONCLUSION: Metabolic tumour volume is a major prognostic factor for DFS and OS in patients with oesophageal squamous cell carcinoma. Higher SUVmax values were paradoxically associated with longer survival. The location of the tumour also appeared to affect prognosis.
PURPOSE: It has been suggested that FDG PET has predictive value for the prognosis of treated oesophageal carcinoma. However, the studies reported in the literature have shown discordant results. The aim of this study was to determine whether pretherapy quantitative metabolic parameters correlate with patient outcomes. METHODS: Included in the study were 67 patients with a histological diagnosis of oesophageal squamous cell carcinoma. Each patient underwent (18)F-FDG PET (4.5 MBq/kg) before chemoradiotherapy. Quantitative analysis was performed using the following parameters: age, weight loss, location, N stage, OMS performance status, MTVp and MTVp' (metabolic tumour volume determined by two different physicians), MTV40% (volume for a threshold of 40 % of SUVmax), MTVa (volume automatically determined with a contrast-based adaptive threshold method), SUVmax, SUVmean and TLG (total lesion glycolysis). RESULTS: MTVp and MTV40% were highly correlated (Pearson's index 0.92). SUVmeanp and SUVmean40% were also correlated (Pearson's index 0.86), as were TLGp and TLG40% (Pearson's index 0.98). Similarly, the parameters obtained with the adaptive threshold method (MTVa, SUVmeana and TLGa) were correlated with those obtained manually (MTVp, SUVmeanp and TLGp). The manual metabolic tumour volume determination (MTVp and MTVp') was reproducible. Multivariate analysis for disease-free survival (DFS) showed that a larger MTVp was associated with a shorter DFS (p = 0.004) and that a higher SUVmax was associated with a longer DFS (p = 0.02). Multivariate analysis for overall survival (OS) showed that a larger MTVp was associated with a shorter OS (p = 0.01) and that a tumour in the distal oesophagus was associated with a longer OS (p = 0.005). The associations among the other parameters were not statistically significant. CONCLUSION:Metabolic tumour volume is a major prognostic factor for DFS and OS in patients with oesophageal squamous cell carcinoma. Higher SUVmax values were paradoxically associated with longer survival. The location of the tumour also appeared to affect prognosis.
Authors: H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Frederic Di Fiore; Valérie Blondin; Anne Hitzel; Agathe Edet-Sanson; Ahmed Benyoucef; Emmanuel Huet; Pierre Vera; Pierre Michel Journal: Dig Liver Dis Date: 2012-08-09 Impact factor: 4.088
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: Dietmar Tamandl; Richard M Gore; Barbara Fueger; Patrick Kinsperger; Michael Hejna; Matthias Paireder; Alexander Haug; Sebastian F Schoppmann; Ahmed Ba-Ssalamah Journal: Eur Radiol Date: 2015-06-05 Impact factor: 5.315
Authors: Xuee Zhu; Chuanhong Liao; Bill C Penney; Feng Li; Mark K Ferguson; Cassie A Simon; Tianming Wu; Haiyan Liu; Yonglin Pu Journal: Nucl Med Commun Date: 2017-02 Impact factor: 1.690
Authors: Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera Journal: Eur J Nucl Med Mol Imaging Date: 2015-02-14 Impact factor: 9.236
Authors: Jian Wu; Chunfeng Lian; Su Ruan; Thomas R Mazur; Sasa Mutic; Mark A Anastasio; Perry W Grigsby; Pierre Vera; Hua Li Journal: IEEE Trans Radiat Plasma Med Sci Date: 2018-09-27
Authors: Lisa Marr; Bernhard Haller; Thomas Pyka; Jan C Peeken; Moritz Jesinghaus; Klemens Scheidhauer; Helmut Friess; Stephanie E Combs; Stefan Münch Journal: Sci Rep Date: 2022-05-03 Impact factor: 4.379
Authors: Arpit Chhabra; Leonard T Ong; Deborah Kuk; Geoffrey Ku; David Ilson; Yelena Y Janjigian; Abraham Wu; Heiko Schöder; Karyn A Goodman Journal: Br J Cancer Date: 2015-12-10 Impact factor: 7.640